Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database

Drug Safety

Volumn 39, Issue 4, 2016, Pages 347-354

  Wahab, Izyan A ^a   Pratt, Nicole L ^b   Ellett, Lisa Kalisch ^b   Roughead, Elizabeth E ^b  

^a CYBERJAYA UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (Malaysia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAHISTINE; BIMATOPROST; BRINZOLAMIDE; FAMOTIDINE; FEXOFENADINE; FUROSEMIDE; GASTROINTESTINAL AGENT; GLUCOSAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LATANOPROST; LODOXAMIDE; LORATADINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PARATHYROID HORMONE[1-34]; PILOCARPINE; PSEUDOMONIC ACID; RANITIDINE; SALAZOSULFAPYRIDINE; TERBINAFINE; TOBRAMYCIN; TRAVOPROST;

ADMINISTRATIVE CLAIMS (HEALTH CARE); ARTICLE; AUSTRALIA; DATA BASE; EDEMA; HEART FAILURE; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; RISK FACTOR; SIGNAL DETECTION; CHEMICALLY INDUCED; DRUG DATABASE; DRUG SURVEILLANCE PROGRAM;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ADVERSE DRUG REACTION REPORTING SYSTEMS; DATABASES, PHARMACEUTICAL; HEART FAILURE; HUMANS;

EID: 84961201241     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0391-8     Document Type: Article

References (47)

1. Han J, Kamber M. Data mining: concepts and techniques. 2nd ed. California: Morgan Kaufman; 2006.
2. Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Exp Opin Drug Saf. 2005;4(5):929–48.
3. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–6.
4. Egberts ACG, Meyboom RHB, Van Puijenbroek EP. Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf. 2002;25(6):453–8.
5. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–21.
6. Gould AL. Practical pharmacovigilance analysis strategies. Pharmacoepidemiol Drug Saf. 2003;12(7):559–74.
7. Lindquist M, Stahl M, Bate A, Edwards IR, Meyboom RHB. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533–42.
8. Lehman HP, Chen J, Gould AL, Kassekert R, Beninger PR, Carney R. An evaluation of computer-aided disproportionality analysis for post-marketing signal detection. Clin Pharmacol Ther. 2007;82(2):173–80.
9. Virnig BA, McBean M. Administrative data for public health surveillance and planning. Ann Rev Pub Health. 2001;22:213–30.
10. Curtis JR, Cheng H, Delzell E, Fram D, Kilgore M, Saag K. Adaptation of bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Med Care. 2008;46(9):969–75.
11. Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf. 2011;20(3):292–9.
12. Brown JS, Kulldorff M, Chan KA, Davis RL, Graham D, Pettus PT, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007;16(12):1275–84.
13. Brown J, Petronis K, Bate A, Zhang F, Dashevsky I, Kulldorff M, et al. Drug adverse event detection in health plan data using the Gamma Poisson Shrinker and comparison to the Tree-based Scan Statistic. Pharmaceutics. 2013;5(1):179–200.
14. Jin H, Chen J, He H, Kelman C, McAullay D, O’Keefe CM. Signaling potential adverse drug reactions from administrative health databases. IEEE Trans Knowl Data Eng. 2010;22(6):839–53.
15. Norén GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20:361–87.
16. Coloma PM, Schuemie MJ, Trifirò G, Furlong L, van Mulligen E, Bauer-Mehren A. Drug induced acute myocardial infarction: Identifying ‘prime suspects’ from electronic healthcare records-based surveillances system. PLoS One. 2013;8(8):e72148.
17. Vegter S, De Jong-Van Den Berg LTW. Misdiagnosis and mistreatment of a common side effect—angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010;69(2):200–3.
18. Garrison SR, Dormuth CR, Morrow RL, Carney GA, Khan KM. Nocturnal leg cramps and prescription use that precedes them: a sequence symmetry analysis. Arch Intern Med. 2012;172(2):120–6.
19. Corrao G, Botteri E, Bagnardi V, Zambon A, Carobbio A, Falcone C, et al. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiol Drug Saf. 2005;14(1):31–40.
20. Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf. 2013;22(5):496–502.
21. Pratt N, Andersen M, Bergman U, Choi N-K, Gerhard T, Huang C, et al. Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study. Pharmacoepidemiol Drug Saf. 2013;22(9):915–24.
22. Australian Government Department of Veterans’ Affairs. Treatment population statistics. Quarterly Report-March 2011; 2011 [cited 2015 May 30]. Available from: http://www.dva.gov.au/aboutDVA/Statistics/Documents/TpopMar2011.pdf.
23. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification index with Defined Daily Doses 2015; 2015 [cited 2015 May 30]. Available from: http://www.whocc.no/atcddd/.
24. Australian Government, Department of Health and Ageing. Schedule of Pharmaceutical Benefits. PBS for health professional 2015; 2015 [cited 2015 May 30]. Available from: http://www.pbs.gov.au/info/healthpro/explanatorynotes/section1/Section_1_2_Explanatory_Notes.
25. National Centre for Classification in Health. International statistical classification of diseases and related health problems, Tenth Revision, Australian Modification (ICD-10-AM). National Centre for Classification in Health, Faculty of Health Sciences, University of Sydney; 2004.
26. Australian Government. Department of Health and Ageing. Therapeutic Goods Administration. Information about prescription medicines in Australia; 2015 [cited 2015 May 30]. Available from: https://www.ebs.tga.gov.au/.
27. Watson RDS, Gibbs CR, Lip GYH. ABC of heart failure: clinical features and complications. BMJ. 2000;320(7229):236–9.
28. Dargie H. Heart failure post-myocardial infarction: a review of the issues. Heart. 2005;91(Suppl 2):ii3–ii6.
29. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf. 2009;18(6):483–91.
30. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiol. 1996;7(5):478–84.
31. Uppsala Monitoring Centre. Latanoprost Safety Report 2010.
32. United States Department of Health and Services. U.S Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Travatan; 2015 [cited 2015 May 30]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21257_Travatan_medr_P1.pdf.
33. Parker RE, Strandhoy JW. A vasoconstrictor cardiogenic chemoreflex induced by prostaglandin F2 alpha. Am J Physiol Heart Circ Physiol. 1981;240(4):H528–32.
34. Schror K. Prostaglandin-mediated actions of the renin-angiotensin system. Arzneimittelforschung. 1993;43(2A):236–41.
35. Castellani S, Paladini B, Paniccia R, Di Serio C, Vallotti B, Ungar A, et al. Increased renal formation of thromboxane A 2 and prostaglandin F 2α in heart failure. Am Heart J. 1997;133(1):94–100.
36. Hill AB. The environment and disease: association or causation? Proc R Soc Med London. 1965;58:295–300.
37. Mira E. Betahistine in the treatment of vertigo. History and clinical implications of recent pharmacological researches. Acta Otorhinolaryngol Ital. 2001;21(3 Suppl 66):1–7.
38. Borow KM, Ehler D, Berlin R, Neumann A. Influence of histamine receptors on basal left ventricular contractile tone in humans: assessment using the H2 receptor antagonist famotidine and the beta-adrenoceptor antagonist esmolol as pharmacologic probes. J Am Coll Cardiol. 1992;19(6):1229–36.
39. Hilleman DE, Mohiuddin SM, Williams MA, Gannon JM, Mathias RJ, Thalken LJ. Impact of chronic oral H2-antagonist therapy on left ventricular systolic function and exercise capacity. J Clin Pharmacol. 1992;32(11):1033–7.
40. Malinowska B, Godlewski G, Schlicker E. Histamine H3 receptors: general characterization and their function in the cardiovascular system. J Physiol Pharmacol. 1998;49(2):191–211.
41. Solomon SD, Wolff S, Jarboe LA, Wolfe MM, Lee RT. Effects of histamine type 2-receptor antagonists cimetidine and famotidine on left ventricular systolic function in chronic congestive heart failure. Am J Cardiol. 1993;72(15):1163–6.
42. Dobnig H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother. 2004;5(5):1153–62.
43. Hagström E, Ingelsson E, Sundström J, Hellman P, Larsson TE, Berglund L, Melhus H, Held C, Michaëlsson K, Lind L, Arnlöv J. Plasma parathyroid hormone and risk of congestive heart failure in the community. Eur J Heart Fail. 2010;12(11):1186–92.
44. Patrik A, Erik R, Ronnie W. Primary hyperparathyroidism and heart disease: a review. Eur Heart J. 2004;25(20):1776–87.
45. Kaul P, Ezekowitz JA, Armstrong PW, Leung BK, Savu A, Welsh RC, et al. Incidence of heart failure and mortality after acute coronary syndromes. Am Heart J. 2013;165(3):379–85.e2.
46. Walker AM. Confounding by indication. Epidemiol. 1996;7(4):335–6.
47. Nor GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20(3):361–87.